Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease
Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease
Amicus Therapeutics today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy for Pompe disease (Myozyme® and Lumizyme®).
Read more in the press release: http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=731504 (external link to the web pages of Amicus Therapeutics) or http://ir.amicustherapeutics.com/common/download/download.cfm?CompanyID=AMTX&FileID=626192&FileKey=edb27c98-d5ec-489b-90fd-5f78497909db&FileName=FOLD_News_2013_1_4_General.pdf (PDF download).
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.